Illumina Stock Forecast, Price & News

Illumina's stock was trading at $246.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ILMN shares have increased by 71.1% and is now trading at $421.00.
View which stocks have been most impacted by COVID-19.

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 3 sell ratings, 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Illumina stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View analyst ratings for Illumina or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Illumina a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Illumina wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among Illumina's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Illumina is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Illumina.

Illumina, Inc. (NASDAQ:ILMN) posted its quarterly earnings data on Thursday, October, 29th. The life sciences company reported $1.02 EPS for the quarter, beating the Zacks' consensus estimate of $0.77 by $0.25. The life sciences company had revenue of $794 million for the quarter, compared to analyst estimates of $713.97 million. Illumina had a trailing twelve-month return on equity of 15.93% and a net margin of 19.70%. The firm's revenue for the quarter was down 12.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.93 earnings per share.
View Illumina's earnings history.

19 brokerages have issued 1 year target prices for Illumina's stock. Their forecasts range from $280.00 to $415.00. On average, they expect Illumina's stock price to reach $333.30 in the next year. This suggests that the stock has a possible downside of 20.8%.
View analysts' price targets for Illumina or view Wall Street analyst' top-rated stocks.

Some companies that are related to Illumina include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), PerkinElmer (PKI), Bio-Techne (TECH), Charles River Laboratories International (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of ILMN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), The Walt Disney (DIS), PayPal (PYPL), salesforce.com (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Illumina's stock is owned by many different retail and institutional investors. Top institutional investors include Douglas Lane & Associates LLC (0.23%), Sarasin & Partners LLP (0.13%), KAMES CAPITAL plc (0.13%), New York State Teachers Retirement System (0.12%), Ardevora Asset Management LLP (0.10%) and DAVENPORT & Co LLC (0.10%). Company insiders that own Illumina stock include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi.
View institutional ownership trends for Illumina.

ILMN stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Waverton Investment Management Ltd, Gateway Investment Advisers LLC, Pacer Advisors Inc., New York State Teachers Retirement System, Douglas Lane & Associates LLC, Nisa Investment Advisors LLC, and Chicago Capital LLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Phillip G Febbo, Robert P Ragusa, Sam Samad, and Susan H Tousi.
View insider buying and selling activity for Illumina or view top insider-selling stocks.

ILMN stock was acquired by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Private Capital Advisors Inc., Sarasin & Partners LLP, KAMES CAPITAL plc, Kestra Advisory Services LLC, Louisiana State Employees Retirement System, YorkBridge Wealth Partners LLC, and Deane Retirement Strategies Inc..
View insider buying and selling activity for Illumina or or view top insider-buying stocks.

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ILMN stock can currently be purchased for approximately $421.00.

Illumina has a market capitalization of $61.47 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis. Illumina employs 7,700 workers across the globe.

The official website for Illumina is www.illumina.com.

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]